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It has been documented recently that left atrial (LA) deformation inAF patients (while inAF) is predictive of subsequent stroke risk.
Additionally, diminished LAdeformation duringAF correlates with the presence of LA blood stasis. Given that endothelial function
is dependent on laminar blood flow, the present study sought to investigate the effect of diminished LA deformation (during
AF) on platelet reactivity and inflammation in AF patients. Patients (𝑛 = 17) hospitalised with AF underwent echocardiography
(while in AF) for determination of peak positive LA strain (LASp). Whole blood impedance aggregometry was used to measure
extent of ADP-induced aggregation and subsequent inhibitory response to the nitric oxide (NO) donor, sodium nitroprusside.
Platelet thioredoxin-interacting protein (Txnip) content was determined by immunohistochemistry. LASp tended (𝑝 = 0.078)




VASc scores. However, mediators of inflammation (C-reactive protein, Txnip) did not correlate
significantly with LASp nor did extent of ADP-induced platelet aggregation or platelet NO response. These results suggest that the
thrombogenic risk associated with LA stasis is independent of secondary effects on platelet aggregability or inflammation.
1. Introduction
Atrial fibrillation (AF) is increasing in global prevalence and
carries with it incremental thromboembolic risk. Currently,
this risk is assessed through the application of clinical




VASc score [1], from which
appropriate antithrombotic therapy may be determined.





VASc score in predicting thromboembolic
events continues to be an ongoing area of investigation: one
such facet of this interest is the association of inflammation
with thromboembolic risk. Just as inflammation is a pivotal
mediator of the pathogenesis of AF [2], it also appears to be
involved in thromboembolic risk. Plasma concentrations of
the inflammatory mediator Galectin-3 correlated positively
[3] and those of the anti-inflammatory mediator adiponectin





potential utility of these biomarkers in refining the prediction
of thromboembolic risk continues to be explored.
An alternative approach to predicting thromboembolic
risk relies ultimately on the concept that avoiding stasis
of regional wall activity is protective [5]: thus the focus is
to investigate the potential of extent of atrial wall motion
for predictive power for incidence of thromboembolism.
Recently, two-dimensional speckle tracking echocardiogra-
phy was used to evaluate the extent of left atrial deformation
(peak positive left atrial strain, LASp) experienced by patients
in AF, correlating diminished LASp with incidence of stroke
[6]. Decreased LASp has also been associated with extent of
left atrial fibrosis [7], incidence of new onset AF [8], and the
occurrence of left atrial blood stasis and thrombus formation
[9].
However, it is also possible that the maintenance of
left atrial deformation limits rheological stimuli towards
thrombosis: nonlaminar blood flow has variously been asso-
ciated with uncoupling of endothelial nitric oxide (NO)
synthase [10], generation of reactive oxygen species [11],
and increased expression of the proinflammatory mediator
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thioredoxin-interacting protein (Txnip) [12, 13]. Given the
aforementioned propensity for blood stasis in the presence
of diminished atrial wall motility and associated risk for
thromboembolism, the present study sought to investigate
potential intersections of LASp and platelet reactivity, as well
as the involvement of the inflammatory mediators C-reactive
protein (CRP) and Txnip, in a cohort of AF patients.
2. Methods
2.1. Study Population. Patients (𝑛 = 17) were included
as a prospectively defined subset of the Standard versus
Atrial Fibrillation SpecificManagement Study (SAFETY) [14,
15]. Inclusion and exclusion criteria for SAFETY have been
reported previously [14]. Patients receiving P2Y
12
receptor
antagonist therapy were also excluded due to the impact such
agents have on platelet ADP response. All patients underwent
transthoracic echocardiography while in AF.
2.2. Clinical. All patients underwent routine clinical and
biochemical investigation upon hospital admission. Standard
echocardiography including Doppler studies was performed
according to established guidelines [16]. Left ventricular
ejection fraction was determined using Simpson’s biplane
method. Measurement of left atrial wall motion was per-
formed as reported by Shih et al. [6], intraobserver coefficient
of variation (CV) was 8.3%, and interobserver CV was 5.1%.
Mean heart rate during transthoracic echocardiography was
84 ± 12 bpm.
2.3. Laboratory. Platelet aggregometry was performed
using whole blood impedance aggregometry as previously
described [17]. Briefly, venous blood was collected from an
antecubital vein into 10mL tubes containing 1 : 10 volume
of acid citrate anticoagulant (2 parts of 0.1M citric acid
to 3 parts of 0.1M trisodium citrate). Aggregation was
induced with ADP (2.5 𝜇M), and responses were recorded
for electrical impedance (Ω) via a computer interface system
(Aggrolink, Chrono-Log, Havertown, Pennsylvania, USA).
The NO donor sodium nitroprusside (SNP, 10 𝜇M) was used
tomeasure platelet response to NO. Inhibition of aggregation
by SNP was evaluated as percentage of maximal aggregation
in the absence of SNP. In order to minimize inaccuracies in
calculation of inhibitory effect of SNP, at least 4Ω of ADP
response was required.
2.4. Statistical Methods. All data for normally distributed
parameters are expressed as mean ± standard deviation
unless otherwise stated. Skewed data are expressed asmedian
and interquartile range (IQR). Where applicable, nonnormal
distributions were transformed using Log or Ln functions.
Univariate correlates of LASp were sought by linear regres-
sion. Data were analyzed using the IBMSPSS Statistics 20 and
GraphPad Prism 6 software packages.
3. Results
The clinical and pharmacological profiles of the study cohort
can be observed in Tables 1 and 2, respectively. A total of
Table 1: Clinical profile of the study cohort.
Sociodemographic profile (𝑛 = 17)
Gender, 𝑛 (% male) 9 (52.9)
Age (yrs) 72 ± 12
Aged ≥ 75 years, 𝑛 (%) 9 (52.9)
Comorbidities
Congestive heart failure, 𝑛 (%) 2 (11.8)
Hypertension, 𝑛 (%) 11 (64.7)
Diabetes mellitus, 𝑛 (%) 4 (23.5)
Prior stroke/TIA, 𝑛 (%) 4 (23.5)
Clinical presentation
Admission heart rate (bpm) 98 ± 31
Plasma creatinine (𝜇M) 86 ± 22





VASc score 3.1 ± 2.0
Table 2: Pharmacological therapy present in the study cohort.
Pharmacological profile (𝑛 = 17)
Antithrombotic therapy
Aspirin, 𝑛 (%) 4 (23.5)
Warfarin, 𝑛 (%) 13 (76.5)
Rate and/or rhythm control therapy
Antiarrhythmics, 𝑛 (%) 5 (29.4)
𝛽 receptor antagonist, 𝑛 (%) 11 (64.7)
RAAS inhibitors
ACE inhibitor, 𝑛 (%) 9 (52.9)
Angiotensin receptor antagonist, 𝑛 (%) 5 (29.4)
Other medications
Statin, 𝑛 (%) 6 (35.3)
Table 3: Echocardiographic profile of the study cohort.
Echocardiographic profile (𝑛 = 17)
Indexed left atrial volume (mm⋅m−2) 39.7 ± 13.0
Left atrial emptying fraction (%) 21.9 ± 11.0
Peak positive left atrial strain (%) 10.6 ± 2.4
Left ventricular emptying fraction (%) 53.7 ± 7.3
8 patients were excluded from analysis because of inade-
quate quality of LASp determination from echocardiographic
records. Patients were typical for an AF population, being
elderly, of moderate stroke risk on the basis of clinical scoring
algorithms, and with relatively preserved renal function. The
majority of patients were receiving oral anticoagulant (war-
farin) therapy and renin-angiotensin-aldosterone system
blockade (angiotensin receptor antagonists or angiotensin-
converting enzyme antagonists), while approximately 1/3
were on lipid-lowering therapies (statins). Echocardiographic
parameters of interest are summarised in Table 3.
The extent of atrial wall motility during AF bore no
significant relationship with platelet reactivity (Figure 1):
correlations between LASp and ADP-induced platelet aggre-
gation, or LASp and platelet response to NO, were both
nonsignificant. It should be noted, indeed, that if anything,
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Figure 1: Relationships between peak positive left atrial strain (LASp) and (a) ADP-induced platelet aggregation (𝑟 = 0.408, 𝑝 = 0.104) or
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Figure 2: No significant correlation was observed between LASp and (a) plasma CRP concentrations (𝑟 = −0.105, 𝑝 = 0.689) or (b) platelet
Txnip content (𝑟 = 0.345, 𝑝 = 0.191).
there was an association (𝑝 = 0.104) between increas-
ing LASp and increasing ADP-induced platelet aggrega-
tion. Similarly, LASp was not significantly associated with
plasma CRP concentrations nor with platelet Txnip con-
tent (Figure 2). A trend towards an inverse association
between CHA2DS2VASc scores and LASp was observed,
while CHA2DS2VASc scores and indexed LA volume were
directly correlated (Figure 3).
4. Discussion
The current study, unique in the literature to date, has
suggested that LASp may vary inversely with clinical indices




VASc score. However, it
has failed to demonstrate any evidence that maintained
LASp might protect against thromboembolism by restoring
homeostasis as regards the inflammatory and autacoid bases
for thrombosis.
Patients with AF are particularly susceptible to the devel-
opment of thrombi in their left atrium, with the presence of
left atrial blood stasis, a significant factor in their formation
[18, 19]. Similarly, left atrial stasis has been correlated with
clinical risk factors and stroke incidence [5, 20]. Such thrombi
are commonly platelet-rich in their morphology [21]; while
not correlated with clinical measures of thromboembolic risk
[22, 23], the platelet hyperaggregability that is present in
patients with AF [24, 25] nonetheless would seemingly have
an integral role in the formation of such thrombi.
One of the factors contributing to platelet hyperaggrega-
bility in this context is potential impairment of the NO sig-
naling pathway (see [26] for review). Effective generation of
NOby endothelialNO synthase is impaired by the presence of
nonlaminar blood flow, such aswhat occurs in the presence of
AF [11, 27, 28]. In theory, the extent of atrial motility present
during AFmay help preserve the functioning of this pathway
through amelioration of blood stasis and, as such, would be
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and indexed LA volume were directly correlated (𝑟 = 0.56, 𝑝 < 0.05).
reflected through measures of platelet reactivity. However, in
our investigation we observed no such correlation between
atrial wall movement and platelet response to ADP or NO.
Similarly, inflammation is regulated in part by NO [29, 30];
specifically Txnip expression is suppressed by the presence
of NO [31, 32]. Yet no correlation was observed between
atrial wallmotion andmarkers of inflammation in the current
investigation.
One potential cause for error in acquisition of LASp data
is variable degrees of tachycardia in the LA [6]. This problem
was minimized because the actual heart rate during LASp
measurementwas 84±12 beats perminute (bpm) and because
multiple views of the LA were incorporated. Reproducibility
of LA strain estimates in AF patients is best achieved by
considering only periods of relative heart rate stability [33].
No particular precautions were taken in this regard, and this
therefore constitutes a potential limitation on accuracy of
data.
The major limitation of the current study is the potential
for type 2 error. However, it seems unlikely from the current
data that any strong correlation has been missed, as regards
the measured physiological parameters. However, it is possi-
ble that platelet responsiveness to NO may not reflect that of
the endocardial endothelium.
According to the principles outlined by Virchow’s triad
[34], the presence of blood stasis in the atria during AF
is a predisposing factor for thrombogenesis. The current
data dissociate this stasis from increased platelet reactivity
and/or inflammation. Given that biomechanical (such as
LASp), as opposed to biochemical, factors are the primary
determinants of left atrial thrombogenesis, it would be
expected that effective maintenance of sinus rhythm in AF
patients would significantly reduce their thromboembolic
risk through improved atrial flow.
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